Ucf-101
Based on 2 publication(s) in Google Scholar
Ucf-101 is a selective and competitive inhibitor of pro-apoptotic protease Omi/HtrA2, with an IC50 of 9.5 μM for His-Omi. Ucf-101 exhibits very little activity against various other serine proteases (IC50>200 μM). Ucf-101 has a natural red fluorescence at 543 nm that is used to monitor its ability to enter mammalian cells. Ucf-101 has a significant cardioprotective effect against MI/R injury and also has certain neuroprotective effect.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.65%
- CAS No.: 313649-08-0
- 화학식: C27H17N3O5S
- 분자량:495.51
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-18234A
Leupeptin hemisulfateProtease Inhibitor -
HY-102007A
Gamitrinib TPP hexafluorophosphateHSP90 Inhibitor -
HY-12495A
ISRIBInhibitor of Integrated Stress Response -
HY-14909
BardoxoloneNrf2 Activator -
HY-B0496
PMSFCathepsin Inhibitor -
HY-125959R
Ucf-101 (Standard)Omi/HtrA2 Inhibitor -
HY-P3042
ChymostatinCathepsin G Inhibitor -
HY-13259C
(R)-MG-132Proteasome Inhibitor -
HY-108552
MG-115Proteasome Inhibitor -
HY-122543
PPACK II diTFAKallikrein Inhibitor -
HY-14877
AnagliptinDPP-4 Inhibitor
Publications Citing Use of MedChemExpress (MCE) Ucf-101
More
Biological Activity
제품 설명
IC50 & Target
IC50: 9.5 μM (His-Omi)[1]
In Vitro
Ucf-101 (20-100 μM; 30 min) inhibits the proteolytic activity of MBP-Omi-(134-458)[1].
?
Ucf-101 (10-100 μM; pretreated for 10 min) inhibits His-Omi-(134-458) activity in a concentration-dependent manner when assayed with His-Omi-(134-458) and β-casein[1].
?
Ucf-101 (1-25 μM; 36 h) inhibits Omi-induced caspase-independent apoptosis of mouse embryo caspase-9 (-/-) null fibroblasts[1].
?
Ucf-101 (1-20 μM; pretreated for 1 h) inhibits the 6-OHDA-induced apoptosis of Parkinson’s disease (PD)-PC12 cells at the low concentration (2.5 μM), and increases the apoptosis rate at the high concentration (≥10 μM)[3].
?
Ucf-101 (2.5 μM; pretreated for 1 h) downregulates the expression of Glucose-regulated protein 78 (Bip/Grp78) and C/EBP homologous protein (CHOP) in PD- PC12 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
? Ucf-101 (1.5 μmol/kg; a single i.p.) improves the APO-induced rotational behavior, increases the TH-positive cells and reverses the reduction of DA neurons in the PD rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult male mice (20-25 g) with myocardial ischemia/reperfusion (MI/R) injury[1]
-
Dosage:0.6, 1.5, 1.8 μmol/kg
-
Administration:I.p. 10 minutes before reperfusion
-
Result:Reduced terminal dUTP nick end-labeling staining, incidence of DNA ladder fragmentation, and infarct size.
Chemical Information
-
CAS No. 313649-08-0
-
Appearance Solid
-
분자량 495.51
-
화학식 C27H17N3O5S
-
Color Orange to red
-
SMILES
O=C(/C(C(N1C2=CC=CC=C2)=O)=C/C3=CC=C(C4=C([N+]([O-])=O)C=CC=C4)O3)N(C5=CC=CC=C5)C1=S
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
J Mol Histol
Ucf-101 alleviates Ischaemia/Reperfusion induced retinal inflammation and injury via suppressing oxidative damage. [Abstract]2024 Aug;55(4):455-464. PMID: 38877338
용액&용해도
In Vitro:
DMSO : 12.5 mg/mL (25.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.79 mg/mL (3.61 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.79 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (17.9 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.67 mg/mL (3.37 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (284 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Cilenti L, et, al. Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2. J Biol Chem. 2003 Mar 28;278(13):11489-94. [Content Brief]
[2]. Liu HR, et, al. Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation. 2005 Jan 4;111(1):90-6. [Content Brief]
[3]. Li Y, et, al. Ucf-101 protects in vivoandin vitro models of PD against 6-hydroxydopamine toxicity by alleviating endoplasmic reticulum stress via the Wnt/β-catenin pathway. J Clin Neurosci. 2020 Jan;71:217-225. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0181 mL | 10.0906 mL | 20.1812 mL | 50.4531 mL |
| 5 mM | 0.4036 mL | 2.0181 mL | 4.0362 mL | 10.0906 mL | |
| 10 mM | 0.2018 mL | 1.0091 mL | 2.0181 mL | 5.0453 mL | |
| 15 mM | 0.1345 mL | 0.6727 mL | 1.3454 mL | 3.3635 mL | |
| 20 mM | 0.1009 mL | 0.5045 mL | 1.0091 mL | 2.5227 mL | |
| 25 mM | 0.0807 mL | 0.4036 mL | 0.8072 mL | 2.0181 mL |
Ucf-101 Related Classifications
HY-125959 Related Classifications
Powered by Bioz